Co strategies. Conclusions These information represent proof that a number of patient-specific neoantigens might be identified via functional evidence of T cell response from peripheral blood devoid of epitope prediction. By profiling organic and CPI-enhanced immunity to neoantigens, a broad catalog of T cell targets may be identified for improvement of immunotherapies that engage T cells against cancer to improve outcomes for sufferers for whom current therapies are insufficient.P356 Genome-scale neoantigen screening employing ATLASTM prioritizes candidates for immunotherapy within a non-small cell lung cancer patient Lila Ghamsari1, Emilio Flano1, Judy Jacques1, Biao Liu1, Jonathan Havel2, Vladimir Makarov2, Taha Merghoub3, Jedd D Wolchok4, Matthew D Hellmann4, Timothy A Chan2, Jessica B Flechtner1 1 Genocea Biosciences, Cambridge, MA, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3Ludwig Collaborative Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA; four Division of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA Correspondence: Jessica B Flechtner ([email protected]) Journal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):PP357 Targeting tumor vasculature using a DNA vaccine against Integrin alpha-2 Proteins supplier endosialin (TEM1 or CD248) Pierini Stefano, Andrea Facciabene, John Facciponte, Stefano Ugel, Francesco De Sanctis, George Coukos University of Pennsylvania, Philadelphia, PA, USA Correspondence: Pierini Stefano ([email protected]) Journal for ImmunoTherapy of Cancer 2016, four(Suppl 1):P357 Background Tumor endothelial marker 1 (TEM1; also known as endosialin or CD248) is often a protein found on tumor vasculature and in tumor stroma. Methods Here, we tested whether or not TEM1 has possible as a therapeutic target for cancer immunotherapy by immunizing immunocompetent mice with Tem1 cDNA fused towards the minimal domain of the C fragment of tetanus toxoid (referred to herein as Tem1-TT vaccine). ResultsJournal for ImmunoTherapy of Cancer 2016, 4(Suppl 1):Page 190 ofTem1-TT vaccination elicited CD8+ and/or CD4+ T cell responses against immunodominant TEM1 protein sequences. Prophylactic immunization of animals with Tem1-TT prevented or delayed tumor formation in various murine tumor models. Therapeutic vaccination of tumor-bearing mice decreased tumor vascularity, enhanced infiltration of CD3+ T cells into the tumor, and controlled progression of established tumors. Tem1-TT vaccination also elicited CD8+ cytotoxic T cell responses against murine tumorspecific antigens. Helpful Tem1-TT vaccination didn’t impact angiogenesis-dependent physiological processes, such as wound healing and reproduction. Conclusions According to these information along with the widespread expression of TEM1 around the vasculature of unique tumor forms, we conclude that targeting TEM1 has therapeutic possible in cancer immunotherapy.the percentage of mice protected against live CT 26 challenge was markedly improved for mice vaccinated with cells treated with HfO2 Fibroblast Growth Factor 7 (FGF-7) Proteins Biological Activity nanoparticles exposed to 6Gy versus 6Gy alone (66 vs 33 respectively). Conclusions HfO2 nanoparticles exposed to irradiation enhanced cancer cells destruction and ICD compared to irradiation alone, suggesting a robust possible for transforming tumor into an efficient in situ vaccine. They might contribute to transform “cold” tumor into “hot” tumor and correctly be combined with a lot of the immunotherapeutic agents across oncology.P358 Hafnium oxide nanoparticle, a radiation enhancer for in.